Roche's Drug Pipeline is Deeper than Market Assumes

Dow Jones09-09 22:59

1459 GMT - Roche Holding's base business is gaining momentum and its drug pipeline offers deeper potential than the market gives it credit for, RBC Capital Markets analysts write in a research note. The crown jewel in the Swiss drugmaker's portfolio is breast-cancer drug candidate giredestrant, which could generate annual sales of as much as $14 billion, according to RBC. Giredestrant has the potential to become a cornerstone therapy in breast cancer, the analysts say. But other drugs in Roche's pipeline such as enicepatide for obesity, pegozafermin for fatty liver disease and fenebrutinib for multiple sclerosis could see upgrades to consensus expectations, they add. RBC starts coverage on Roche with an outperform recommendation and a target price of 400 Swiss francs.Shares fall 0.8% to 347.70 francs.

At the request of the copyright holder, you need to log in to view this content

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment